Agilent Technologies' Michael McMullen Has Sold $138.5M in Stock Over 266 Transactions
Michael McMullen, Director at Agilent Technologies, has executed 266 insider transactions totaling $138.5M in career stock sales with zero purchases, including a $7.8M single-day sale at $150/share.
Michael R. McMullen, Director at Agilent Technologies (A), has filed 266 insider transactions totaling $138.5 million in career stock sales with zero purchases. His most significant recent sale was a $7.8 million block trade of 52,297 shares at $150 per share in March 2024.
The Numbers
| Metric | Value |
|---|---|
| Career Sell Value | $138.5M |
| Career Buy Value | $0 |
| Total Transactions | 266 |
| Last Transaction | 2024-03-08 |
| Shares Remaining | 253,908 |
Recent Activity
| Date | Type | Shares | Price | Est. Value |
|---|---|---|---|---|
| 2024-03-08 | Sell | 52,297 | $150.00 | $7.8M |
| 2023-12-13 | Exercise+Sell | 2,751 | $130.00 | $358K |
| 2023-12-07 | Exercise+Sell | 62,467 | $130.00 | $8.1M |
McMullen's selling pattern shows concentrated large-block dispositions rather than daily trickle sales. The December 2023 exercise-and-sell of 62,467 shares followed by the March 2024 $7.8M block suggests periodic monetization events, likely timed around vesting schedules or 10b5-1 plan execution windows.
What It Means
McMullen's $138.5M in career sales came entirely through systematic liquidation as a board member and former CEO of Agilent. Unlike many insiders who maintain token purchase activity, McMullen has made exactly zero open-market buys. The 266 transactions represent a methodical, multi-year conversion of equity compensation into cash.
With 253,908 shares still remaining, McMullen maintains a meaningful residual stake worth approximately $35M+ at current prices — a notable contrast to some insiders who sell down to near-zero. For Agilent investors, the key question is whether the current pause in selling since March 2024 reflects a deliberate hold or simply an exhausted tranche of exercisable options. The company's positioning in life sciences and diagnostics instruments remains strong, making the retained stake a potential positive signal.
What to Watch
- Whether McMullen resumes selling in 2026 after a nearly two-year pause
- Agilent's instrument demand recovery and China market rebound trends
- New option grants or equity awards that could trigger fresh selling activity
- Board composition changes that might affect McMullen's ongoing insider status
Related Research
Explore all researchFIL Ltd's Q4 2025 13F shows $133.60B in reported value, led by MSFT and a diversified institutional tail.
Apr 24, 2026
Qube Research & Technologies Ltd's Q4 2025 13F shows $98.44B in reported value, led by NVDA and a diversified institutional tail.
Apr 24, 2026
Swedbank AB's Q4 2025 13F shows $103.37B in reported value, led by NVDA and a diversified institutional tail.
Apr 24, 2026
NORDEA INVESTMENT MANAGEMENT AB's Q4 2025 13F shows $116.45B in reported value, led by NVDA and a diversified institutional tail.
Apr 24, 2026
RHUMBLINE ADVISERS's Q4 2025 13F shows $123.69B in reported value, led by NVDA and a diversified institutional tail.
Apr 24, 2026